IL-1β in breast cancer bone metastasis

Jiabao Zhou[1], Claudia Tulotta[2] and Penelope D. Ottewell[1] (iD)

[1]Department of Oncology and Metabolism, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK and [2]Institute for Experimental Pathology (ExPat), Center for Molecular Biology of Inflammation (ZMBE), Westfälische Wilhelms-Universität (WWU), 48149 Münster, Germany

Abstract

Bone is the most common site for advanced breast cancer to metastasise. The proinflammatory cytokine, interleukin-1β (IL-1β) plays a complex and contradictory role in this process. Recent studies have demonstrated that breast cancer patients whose primary tumours express IL-1β are more likely to experience relapse in bone or other organs. Importantly, IL-1β affects different stages of the metastatic process including growth of the primary tumour, epithelial to mesenchymal transition (EMT), dissemination of tumour cells into the blood stream, tumour cell homing to the bone microenvironment and, once in bone, this cytokine participates in the interaction between cancer cells and bone cells, promoting metastatic outgrowth at this site. Interestingly, although inhibition of IL-1β signalling has been shown to have potent anti-metastatic effects, inhibition of the activity of this cytokine has contradictory effects on primary tumours, sometimes reducing but often promoting their growth. In this review, we focus on the complex roles of IL-1β on breast cancer bone metastasis: specifically, we discuss the distinct effects of IL-1β derived from tumour cells and/or microenvironment on inhibition/induction of primary breast tumour growth, induction of the metastatic process through the EMT, promotion of tumour cell dissemination into the bone metastatic niche and formation of overt metastases.

Introduction

Breast cancer has recently overtaken lung cancer as the most commonly diagnosed cancer worldwide with >680 000 deaths reported in 2020 (Ref. 1). Metastatic spread to other organs is the main cause of death from breast cancer and around 70–80% of metastases will develop in bone. Bone metastases generally form in bones with a high marrow content such as the ribs, spine or the long bones. This condition has a long latency, and is not usually detected until several years after the patient has completed treatment for their primary disease. The first indication of tumour relapse in bone is often the result of a patient presenting in the clinic with tumour-associated skeletal-related events including pathological fractures and spinal cord compression accompanied by severe pain and hypercalcaemia (Ref. 2). At this stage, the disease is currently considered incurable, therapeutic strategy switches to, predominantly, palliative care to reduce pain and increase the quality of life and survival drops to ∼2–3 years after initial diagnosis of bone involvement (Ref. 3). Therefore, there is an urgent need to identify biomarkers and targetable drivers of breast cancer bone metastasis. This would enable identification of patients whose tumours are likely to relapse in bone and allow earlier treatment delivery and development of more effective therapeutic strategies.

Interleukin-1β (IL-1β) as a biomarker and potential target for inhibiting/treating breast cancer bone metastasis

High levels of IL-1 in tumours are a predictor of poor prognosis in several cancer types including lung, breast, melanoma and metastatic prostate (Refs 4–7). The IL-1 family is an 11-member group of endogenous cytokines involved in inflammation and immune response, including cytokine activators: IL-1 alpha (IL-1α), IL-1 beta (IL-1β) and the cytokine antagonist, IL-1 receptor antagonist (IL-1Ra). Through binding the type 1 receptor (IL-1R1), IL-1α or IL-1β induces downstream signalling cascades and the transcription of downstream genes (Fig. 1) (Ref. 8). Both IL-1α and its precursor (pro-IL-1α) are biologically active IL-1R1 ligands, but only mature IL-1β has biological activity after its precursor (pro-IL-1β) is cleaved by caspase-1 (Refs 9, 10). In primary human breast cancers, in addition to IL-1β produced by tumour cells, the main cellular sources of IL-1β are myeloid cells, especially monocytes and dendritic cells (DCs), as well as endothelial cells. When tumours are growing in the bone microenvironment, osteoblasts and bone marrow cells are also stimulated to secrete IL-1β. Several of these cell types, including tumour cells, do not just secrete IL-1β they also express IL-1R1 allowing both, autocrine and paracrine IL-1 signalling to exert pro/anti-tumour effects dependent on the makeup of the local environment (Refs 11, 12). Through interactions with different cell types, IL-1β participates in several physiological and pathological processes including proliferation, migration, invasion and apoptosis and appears to have organ-specific effects on tumour immune responses to promote pro- or anti-tumour responses (Refs 5, 13).

CAMBRIDGE
UNIVERSITY PRESS

Fig. 1. IL-1 pathway. IL-1β is produced as inactive proform in response to pro-inflammatory signals. Activation of pro-IL-1β is initiated through cleavage by caspase-1 to 17 kD active IL-1β. IL-1β signals by assembling a trimeric receptor complex with IL-1R1 and IL-1RacP. This trimeric complex rapidly recruits, assembles and further modifies Mdy88, IRAKs and TRAF6 which initiates downstream NF-κB-mediated transcription, subsequent cytokine production and pathways that regulate tumourigenesis.

IL-1β expression in primary breast cancers has been shown to correlate with breast cancer stage: ex vivo analysis of primary samples in the laboratory demonstrated that secretion of IL-1α, IL-1β and IL-1Ra was significantly higher in tumour tissues compared with non-cancerous tissue and IL-1β was significantly higher in stage II or stages III–IV breast cancer compared with stages 0–I (Ref. 12). In addition, TCGA and METABRIC datasets both show that *IL-1B* gene expression levels are significantly higher in triple negative breast cancer compared with other subtypes of breast cancer (Ref. 14). Moreover, a 10-year follow-up analysis of *IL-1B* expression in primary tumour samples taken from 1189 patients with stage II/III enrolled onto the phase III AZURE trial (ISRCTN79831382) before randomisation and commencement of treatment (randomised (1:1) to standard adjuvant therapy alone (control) or with zoledronic acid (zoledronate)) showed a strong correlation between IL-1β in tumour cells and distant recurrence at any site ($P = 0.0016$) (Ref. 5). Furthermore, patients with higher IL-1β in their primary tumours were more likely to develop bone metastasis ($P = 0.02$ and $P < 0.0001$ from independent studies) (Refs 5, 15). Interestingly, data from patient samples from the AZURE study showed no correlation between IL-1β expression and ER/HER2 (oestrogen/human epidermal growth factor receptor 2) status, suggesting that IL-1β may be an indicator of metastatic potential independent of breast cancer type. Interestingly, in a separate study focused on ER −ve breast cancer, release of high levels of IL-1α and IL-1β in serum released by circulating tumour cells (CTCs) was associated with an increased risk of death (Ref. 16). Taken together, these data indicate that tumour-derived IL-1β is directly correlated with the breast cancer stage and is an indicator of future metastasis.

Direct evidence that tumour-derived IL-1β can promote tumour cell spread to bone and drive metastatic outgrowth in this environment has come from mouse models: human triple negative MDA-MB-231 breast cancer cells that have been manipulated to specifically home to the bone microenvironment following intra-venous injection in BALB/c nude mice, express high levels of *IL-1B* (Ref. 15). Furthermore, in humanised mouse models, expression of this cytokine is upregulated by $192 \pm 82\%$ in MDA-MB-231 and $500 \pm 253\%$ in ER +ve MCF7 cells that spontaneously metastasise from the mammary fat pad to human bone implants compared with cells that did not metastasise (Ref. 17). Importantly, overexpression of *IL-1B* in breast cancer cells by genetic manipulation significantly increases the

number of mice that develop bone metastases following intra-venous injection from 12% in mice injected with MDA-MB-231 control cells to 75% in mice injected with MDA-MB-231-IL-1β + cells. Overall, these data suggest that IL-1β produced by the tumour cells plays a pivotal role in the homing of these cells to the bone environment (Ref. 5). Although IL-1β produced by tumour cells appears to promote breast cancer relocation to bone, once in bone the process of metastatic outgrowth appears to be driven by a combination of IL-1β produced by tumour cells and cells from the local environment: arrival of tumour cells in bone leads to an increase in IL-1β secretion by tumour cells, osteoblasts, endothelial cells and components of the bone marrow which, in turn, stimulates IL-1β driven Wnt signalling in cancer stem cells (CSCs) and subsequent development of overt metastases (Refs 5, 18). The importance of IL-1β from the bone microenvironment on metastatic outgrowth is evidenced in mouse models that are globally deficient in IL-1β (IL-1β$^{-/-}$). Intra-venous injection of syngeneic E0771 cells into IL-1β$^{-/-}$ mice impaired the development of bone metastasis to 22.2% in IL-1β-deficient (IL-1β$^{-/-}$) animals compared with 66.7% in control IL-1β$^{fl/fl}$ mice (Ref. 13). Furthermore, pharmacological inhibition of IL-1 by the IL-1Ra, anakinra, or the human-specific anti-IL-1β antibody, canakinumab, has been shown to almost eliminate the development of bone metastases in various types of mouse models including, syngeneic (anakinra only), ER +ve and ER −ve human tumour-specific, as well as ER +ve and ER −ve models of spontaneous metastasis of human-derived breast cancer cell lines to human bone implants (Refs 5, 17–19).

Despite being an indicator of poor prognosis in breast cancer and promoting metastatic outgrowth in bone, IL-1β appears to have opposing effects on the primary tumour. Conflicting studies show that IL-1β either promotes or reduces growth of primary tumours and/or metastatic outgrowth of tumours in the lung dependent on the mouse's immunological background and the tumour stage when anti-IL-1 therapies were administered (Refs 5, 13, 19–21). The majority of studies indicate that IL-1β from the microenvironment is responsible for suppressing tumour growth at the primary site, through stimulating an anti-tumour immune response (Refs 13, 22), whereas IL-1β produced by tumour cells causes these cells to undergo epithelial to mesenchymal transition (EMT) and spread to other organs (Refs 5, 23, 24). Therefore, IL-1β in soft tissues has both pro- and anti-tumour effects and inhibition of this cytokine decreases EMT preventing tumour cells from metastasising, but supports an

epithelial phenotype to favour tumour proliferation while also reducing infiltration of innate immune cells, potentially, preventing anti-tumour immunological responses.

In this review, we discuss the effects of IL-1β on primary breast cancer and bone metastasis to assess its potential as therapeutic target to prevent the onset and growth of bone metastases.

IL-1β in the metastatic cascade of breast cancer

Breast cancer bone metastasis is a complex multi-step process: tumour cells escape from mammary gland to the blood, survive in the circulation, home to the bones and eventually form metastatic tumours in the bones (Fig. 2). These tumour cells entering the circulation or entering distant sites are called circulating tumour cells (CTCs) or disseminated tumour cells (DTCs), respectively (Refs 25, 26).

Genes associated with IL-1B alteration in breast cancer bone metastasis

The initial stage of the metastatic cascade requires tumour cells to escape from the primary site (Ref. 27). In order to do this, primary tumour cells acquire specific genetic and epigenetic alterations that enable them to invade surrounding tissue, degrade the basement membrane of the vasculature and detach from the primary tumour (Ref. 27). Using humanised mouse models of human breast cancer metastasis to human bone implants, Tulotta et al. identified a significant increase in IL-1B gene expression in CTCs and metastatic tumours in the bone compared with primary tumours in the fat pads (Ref. 5). In addition, various genes associated with EMT (E-cadherin, N-cadherin and JUP) were also significantly changed in these metastases compared with primary tumours (Ref. 5). This association with upregulated IL-1B and genes associated with EMT and development of breast cancer metastasis, is not unique to the humanised model, and it has also been reported in spontaneous tumour development and metastasis (MMTV-Py8119 model), as well as in bone homing human MDA-MB-231 cells (Refs 15, 21).

IL-1β and EMT, migration and invasion in breast cancer

EMT enables tumour cells to acquire a more invasive phenotype (Ref. 27). Tumour cells undergoing EMT lose their gap junctions and apical-basal polarity and increase their motility to enable enhanced migratory and invasive phenotype (Ref. 28). The majority of evidence that this process can be driven by IL-1β has come from in vitro experiments.

Genetic manipulation of ER +ve and ER −ve breast cancer cell lines to overexpress IL-1β (MDA-MB-231-IL-1β+, T47D-IL-1β+ and MCF7-IL-1β+) results in both genotypic and phenotypic alterations associated with EMT. IL-1β overexpressing cells expressed significantly less E-cadherin and γ-catenin and more N-cadherin, at both gene and protein levels, compared with the relevant wild-type controls (Ref. 5). Meanwhile, IL-1β overexpressing cells from this as well as other studies have demonstrated more aggressive invasion and migration abilities in scratch and transwell invasion experiments, in vitro, compared with wild-type control cells (Refs 5, 13, 29). Additionally, studies have indicated that IL-1β induced triple-negative breast cancer cells to produce IL-6, and increase tumour proliferation, EMT and drug resistance through the IL-6/JAK2/STAT3 pathway (Ref. 30). Moreover, EMT and stem cell-like phenotypes of tumour cells had been attenuated by administration of anti-IL-6 or anti-IL-1β antibodies (Refs 5, 30).

Matrix metalloproteinases (MMPs) are a group of enzymes that degrade the extracellular matrix (ECM) (Ref. 29). A recent study has showed that administration of exogenous IL-1β promoted MMP-9 production in non-metastatic MCF-7 breast cancer cells leading to acquisition of invasive ability by activating focal adhesion kinase and proto-oncogene tyrosine-protein kinase Src (Src) (Ref. 31). Moreover, exogenous IL-1β has been shown to induce MMP-2 to degrade the ECM or hard mineralised matrix of bones by increasing β-catenin translocation (Ref. 32). In addition to effects of exogenous IL-1β, IL-1β produced by MDA-MB-231 breast cancer cells under hypoxia also promoted an invasive phenotype in cancer-associated fibroblasts (CAFs) by paracrine feed-forward signalling (Ref. 14). This cross-talk between CAFs with cancer cells and tumour microenvironment (TME) are also pivotal for the degradation of the ECM (Ref. 29). Importantly, these invasive cancer phenotypes triggered by IL-1β/IL-1R signalling were reversed after IL-1 inhibition with the IL-1R1 antagonist anakinra (Refs 5, 18, 20). These data suggest that EMT induced by IL-1β is one of the main reasons that IL-1β drives the early stages of breast cancer metastasis.

IL-1β and angiogenesis in breast cancer

Angiogenesis is a fundamental marker of malignant tumours and metastatic tumours. Tumour cells and cells that make up the TME, including endothelial cells, mesenchymal cells and immune cells, can secrete a variety of cytokines that promote angiogenesis. IL-1β/IL-1R signalling has been shown to mediate angiogenesis by indirectly inducing vascular endothelial growth factor (VEGF) expression and secretion in various types of cells in a multitude of tumours including breast cancer (Ref. 33) and it has been hypothesised that IL-1β synergises with VEGF in the early angiogenic response (Ref. 34). Administration of anakinra significantly decreased the percentage of Ki67 positive cells and the number of CD31, CD34 positive micro-vessels in subcutaneous breast cancer tumours, but had no effect on the percentage of caspase-3 positive cells (Refs 19, 20). This suggests that inhibition of IL-1β/IL-1R1 signalling can also show an anti-tumour effect by inhibiting angiogenesis.

IL-1β and breast cancer bone homing and colonisation

The next step of the metastatic cascade is accumulation of DTCs in secondary metastatic organs and lodging of tumour cells in the pre-metastatic niches that support the dormancy and/or outgrowth of DTCs (Ref. 27). Several breast cancer cells have a high affinity for bone in particular areas that make up the metastatic niche(s): the endosteal niche (consisting of osteoblasts and haematopoietic stem cells) and the peri-vascular niche (Refs 18, 35, 36). Nutter et al. have established breast cancer bone homing cells (MDA-IV) by repeatedly passing MDA-MB-231 cells, in vivo, and found that IL1B gene expression and IL-1β secretion were significantly increased in MDA-IV compared with parental MDA-MB-231 cells (Ref. 15). Furthermore, MDA-IV cells have been shown to home to the peri-vascular, endosteal and haematopoietic stem cell niches in mouse bone (Ref. 37) which suggests that IL-1β is associated with breast cancer bone homing (Ref. 15). In support of this hypothesis, injecting MDA-MB-231 breast cancer cells that over express IL-1β into the tail vein of BALB/c nude mice significantly increases the number of mice that develop bone metastasis (as discussed previously) (Refs 5, 19). It is widely accepted that the CXCL12–CXCR4 axis plays a pivotal role in the progression and metastasis of breast cancer: stromal cell-derived CXCL12 is expressed in secondary metastatic sites including by osteoblasts, haematopoietic stem cells and endothelial cell that make up the bone metastatic niche. It is believed that CXCL12 attracts metastatic tumour cells that with upregulated CXCR4 receptor (Ref. 38). Experiments performed by Valdivia-Silva et al. indicated that IL-1β stimulation increases the expression of CXCR4 on MCF-7 cells which, in turn,

Fig. 2. Effects of IL-1β on the breast cancer bone metastatic cascade and 'vicious cycle of bone metastases'. Black arrows indicate the breast cancer bone metastatic cascade: tumour cells escape from mammary gland to the blood, survive in the circulation, home to the bones and eventually form metastatic tumours in the bones. Blue arrows indicate how IL-1β in the bone microenvironment drives the 'vicious cycle of bone metastases'.

displayed a higher migration index to CXCL12 (Ref. 39). Moreover, MDA-MB-231-derived IL-1β was shown to activate mesenchymal stem cells and induce various chemokines including CXCL12 to facilitate trans-endothelial migration of breast cancer cells to the bone marrow (Ref. 40). These data suggest that IL-1β promotes interaction between CXCR4 and CXCL12 and thus induce breast cancer bone homing.

Dissemination of breast cancer cells into the bone marrow is an early event, likely to occur before clinical detection of the primary disease (Ref. 26). Studies have shown that 30–40% of breast cancer patients have DTCs in their bone marrow, and for most patients these cells will remain dormant for long periods (several months to years) prior to proliferating into overt metastases (Refs 41–43). Therefore, the long-term survival of DTCs, in bone, is a risk factor for recurrence of breast cancer several years after the removal of the primary breast tumour (Refs 25, 44). After a phase of dormancy, components of the metastatic niche can re-activate DTCs. Although the whole mechanism of how this happens is yet to be identified, strong evidence suggests that bone-derived transforming growth factor-beta (TGF-β1) and IL-1β are able to reactivate dormant DTCs stimulating metastatic outgrowth (Refs 45, 46). There is evidence that when these activated DTCs undergo EMT, they acquire stem cell-like properties, thus becoming CSCs to finally enable the formation of overt metastases (Refs 39, 47, 48). Eyre *et al.* found that bone marrow-derived IL-1β enables breast CSCs to form metastatic colonies in

the bone via activation of intracellular NF-κB/CREB signalling and Wnt ligand production by cancer cells, and neutralisation of IL-1β inhibited the induction of colony formation (Ref. 18). In addition, Sarmiento-Castro *et al.* found that IL-1β/IL-1R1 signalling is likely to be important for CSCs to drive ALDH+ activity of anti-oestrogen-resistant in breast cancer (Ref. 49). These data suggest that targeting IL-1β signalling can prevent breast cancer bone metastasis by impairing both bone homing of CSCs and colony formation in the bone environment.

IL-1β and vicious cycle of breast cancer bone metastasis

As previously described, bone cell-derived IL-1β enables reactivation of dormant DTCs (Refs 45, 46), whereas tumour-derived IL-1β promotes expansion of the bone metastatic niche resulting in tumour cell proliferation (Ref. 5). Newly awakened and actively proliferating DTCs secrete a variety of growth factors, such as parathyroid hormone-related protein (PTHrP) and IL-1β, that stimulate the activity of osteoblasts and osteoclasts through the RANKL/RANK/OPG pathway leading to increased bone remodelling (reviewed in Refs 46, 50). Increased bone resorption leads to a positive feedback loop in which matrix-derived growth factors, such as TGF-β are released into the metastatic microenvironment further stimulating proliferation of metastatic tumour cells which, in turn, produce more PTHrP and IL-1β (Refs 36, 46, 50). Moreover, IL-1β has been shown to promote expansion of

the bone metastatic niche promoting additional tumour cells into the environment that can subsequently proliferate and increase metastatic burden. Taken together, these data suggest that IL-1β plays a vital role in this 'vicious cycle' of osteolytic metastasis (Fig. 2). The importance of IL-1β from both tumour cells and the microenvironment in this 'vicious cycle' have been demonstrated in mouse models: injecting BALB/c nude mice intravenously with MDA-MB-231-IL-1β+ resulted in mice developing significantly larger osteolytic lesions compared with mice injected with MDA-MB-231 wild-type cells (Ref. 5). Similarly, IL-1β over-expressing MDA-MB-231 cells also lead to increased lytic lesions in BALB/c nude mice compared with wild-type cells following intra-cardiac injection. Although tumour cell-derived IL-1β clearly has effects on tumour growth and lesion development in bone, evidence suggests that either overall concentrations of IL-1β in the local environment or IL-1β secreted from other cell types within the tumour environment may dominate the tumourigenic effects of this cytokine as IL-1β$^{-/-}$ mice develop far fewer and much smaller bone metastases compared with, control, IL-1β$^{fl/fl}$ mice following intra-cardiac injection of E0771 cells (Ref. 13). Furthermore, inhibiting IL-1β signalling in mouse bone by administration of anakinra or canakinumab significantly increases bone volume and inhibits both osteoclast and osteoblast activity compared with bones from control mice in several breast cancer models in vivo (Refs 5, 18, 19) and IL-1β has also been shown to have direct stimulatory effects on osteoblast and osteoclast proliferation/differentiation in vitro (Refs 5, 51). It is, therefore, likely that inhibition of IL-1β signalling prevents/reduces growth of breast cancer cells in bone through both inhibiting activation of dormant CSCs and through disrupting the vicious cycle.

IL-1β in tumour immune response

There are strong and clear evidence that IL-1β promotes breast cancer bone metastases and that IL-1β-targeted therapies are able to inhibit these pro-metastatic effects (Fig. 3). However, the effects of inhibiting IL-1β on primary breast cancers are still far from clear. Treatment of primary 4T1, E0771 and MDA-MB-231 cells with anakinra has led to contrasting results with most researchers showing increased growth of tumours in the fat pad (Refs 5, 52). However, other studies have shown reduced primary tumour growth of 4T1 and MDA-MB-231 cells following administration of the same dose of anakinra (Refs 19, 20). Treatment with canakinumab seems to always lead to increased tumour growth and it is tempting to think that this may be because of differences in targeting signalling via the IL-1R with anakinra and neutralisation of IL-1β with canakinumab. However, data from IL-1β knockout mice suggest that the answer is not that simple: Tulotta et al. showed that E0771 cells grew more rapidly in IL-1β$^{-/-}$ C57BL/6 mice compared with control mice (IL-1β$^{fl/fl}$) mice following orthotopic injection (Ref. 13). Similarly, other researchers have shown that 4T1 tumours initially grow following injection into IL-1β$^{-/-}$ mice, but these quickly regress resulting in much smaller tumours in IL-1β$^{-/-}$ mice compared with control (Ref. 53). In contrast, Kiss et al. demonstrated delayed tumour growth in IL-1β$^{-/-}$ C57BL/6 mice following orthotopic injection with E0771 cells compared with control mice (IL-1β$^{fl/fl}$) (Ref. 11). Although these data are contradictory, experiments have been performed in mice from a variety of backgrounds, with various immunological impairments and/or anti-IL-1 treatments have commenced at different stages of tumour growth. Effects of IL-1β in the microenvironment fluctuates between anti-tumour and pro-tumour through driving the infiltration of innate anti-tumour immune cells as well as establishing an immunosuppressive microenvironment by increasing the infiltration of myeloid-derived suppressor cells (MDSCs), therefore it is not surprising that IL-1β may have differing effects dependent on tumour stage and the immunological background of the host. Therefore, understanding the role of IL-1β in tumour immune response in breast cancer is crucial to the study of anti-IL-1β therapies in the treatment of breast cancer bone metastases.

Neutrophils

Neutrophils display phenotypic and functional heterogeneity (Ref. 54) and, in cancer, anti-tumourigenic N1-like or pro-tumourigenic N2-like phenotypes have been described (Ref. 55). Several cytokines, such as IL-1β produced by tumour cells, regulate neutrophil recruitment (Ref. 56). In addition, neutrophils expressing high level of IL-1β also directly interact with CTCs to support cell cycle progression in circulation and to facilitate metastatic seeding (Ref. 57). Although experiments performed by Tulotta et al. and Kiss et al. showed IL-1β$^{-/-}$ mice have different breast cancer outcomes, in terms of primary tumour growth, both studies showed reduced numbers of tumour infiltrating neutrophils in the primary site. Additionally, Kiss et al. reported reduced systemic mobilisation and numbers of neutrophils in the circulation in IL-1β$^{-/-}$ mice compared with control. Interestingly, Tulotta et al. found that the lack of microenvironment-derived IL-1β resulted in decreased infiltration of Myeloperoxidase (MPO) + neutrophils which is consistent with anti-tumour effects observed in breast cancer patients where infiltration of MPO+ neutrophils have been associated with a significantly better overall survival (P < 0.001) (Refs 13, 58). Moreover, although Kiss et al. found that loss of microenvironment-derived IL-1β abrogated expansion of circulating CD45 + CD11b + Ly6G+ neutrophils (Ref. 11) increased CD45 + CD11b + Ly6G+ neutrophils have been found in the bone marrow of IL-1β$^{-/-}$ mice following intracardiac-injection of E0771 cells suggesting that IL-1β may be required to mobilise these neutrophils from the bone environment to soft tissue (Ref. 13).

IL-1β has also been shown to regulate both pro- and anti-metastatic effects of neutrophils on the metastatic outgrowth of breast tumours in the lung. Xiao et al. demonstrated that production of cathepsin C by breast cancer cells in the lung activated IL-1β in local neutrophils. This, in turn leads to the recruitment of more neutrophils from the circulation, increases production of reactive oxygen species, finally leading to the formation of neutrophil extracellular traps (NETs). The release of these NETs in the lung causes degradation of thrombospondin 1, promoting metastatic outgrowth of tumour cells disseminated in this organ (Ref. 59). In contrast, Zhao et al. reported that IL-1β could induce the recruitment of anti-tumour neutrophils to the lung and this resulted in blocking lung metastasis (Ref. 60).

In a slight contradiction to the aforementioned studies, Comes et al. observed that inhibiting IL-1 by IL-1R antagonist had no significant effect on the numbers of neutrophils that infiltrated tumours, but, instead, reduced the polarisation of neutrophils to the N2-like phenotype (Ref. 61). Therefore, IL-1β may be able to exert dual effects, both recruiting neutrophils to the TME and stimulating their polarisation to a tumour-killing or tumour-promoting phenotype. The difference in recruitment or phenotype of neutrophils induced by IL-1β in primary tumours or soft tissue metastasis may lead to contradictory results. However, inhibition of IL-1β consistently impairs bone metastasis and whether this is regulated by neutrophils will require further studies.

Macrophages

Similarly to neutrophils, there are two populations of macrophages in the TME: M1-like and M2-like (Ref. 62). M1-like

Fig. 3. Tumour and microenvironment-derived IL-1β in primary breast tumour and bone metastasis. In the primary tumour, microenvironment-derived IL-1β drives the recruitment of myeloid cells such as neutrophils that may act as a brake of tumour proliferation *in situ*. However, tumour-derived IL-1β induces EMT, promoting the initiation of the metastatic cascade, leading to cancer cell spreading to bone. In bone, IL-1β supports niche expansion and enables disseminated CSCs to form metastatic colonies. Inhibition of tumour- or microenvironment-derived IL-1β enhances primary tumour growth, however impairs bone metastasis, suggesting niche-dependent functions of IL-1β. Disabling both tumour and microenvironment-derived IL-1β by inhibiting IL-1β cognate receptor IL-1R1, in combination with therapies that stimulate immunogenic cell death, impairs both primary tumour growth and bone metastasis.

macrophages are anti-tumour macrophages that can mediate cytotoxicity and antibody-dependent cell-mediated cytotoxicity to kill tumour cells; whereas M2-like macrophages have pro-tumour effects through the promotion of immunosuppression by inhibiting T cells (Ref. 62). Macrophages are one of the main sources of IL-1β, and tumour cells can stimulate macrophages to produce IL-1β. IL-1β can also promote the infiltration and differentiation of monocytes into macrophages within the primary tumour: there is an auto-amplification loop between macrophages and breast cancer, resulting in further increased expression of IL-1β by both macrophages and breast cancer cells to promote the development of cancer (Ref. 63). This hypothesis has been further confirmed in studies showing that macrophage depletion significantly decreases serum IL-1β and delays breast cancer progression in a mouse model (Ref. 64). IL-1β-deficient mice, in which primary tumour growth is significantly delayed, have far fewer macrophages compared with their control counterparts (Ref. 53). Moreover, in the absence of IL-1β, macrophages have been confirmed to be important for the accumulation and activation of CD8+ cells in breast cancer (Ref. 11).

Macrophage number is not the only factor that influences the effects of this immune cell type on tumourigenesis. Several studies show that polarisation of macrophages from an M1-like to an M2-like phenotype is a more important driver of this process

(reviewed in Ref. 65), and in addition to promoting anti-tumour effects, IL-1β can also induce pro-tumour effects through altering macrophage polarisation and location: mouse model studies comparing tumours isolated from IL-1β$^{-/-}$ and IL-1β$^{fl/fl}$ mice demonstrated that in the presence of IL-1β in the microenvironment the majority of macrophages recruited to the tumour were inducible nitric oxide synthase (iNOS+) M1-like macrophages and no differences in infiltration of CD163+ M2-like macrophages were observed. Moreover, IL-1β appeared to be important for determining the location of these cells. In primary tumours isolated from control (IL-1β$^{fl/fl}$) mice, iNOS+ cells have been shown to be located in viable areas of tumours whereas CD163+ macrophages localise to areas of necrosis. This locational bias is lost in IL-1β$^{-/-}$ mice (Ref. 13) suggesting that IL-1β attracts tumour-killing M1-like macrophages away from the areas of necrosis and into healthy tumour tissue where they can exert maximum anti-tumour effects. These data further explain how microenvironment-derived IL-1β can reduce primary tumour by recruitment and infiltration of innate immune cells.

Although IL-1β appears to exert significant anti-tumour effects on primary tumours through the recruitment of macrophages, the same does not seem to happen in the bone microenvironment. The presence of CD45 + CD11b+ myeloid cells is significantly lower in bone marrow compared with primary tumours

(Ref. 11) furthermore no significant differences in the accumulation of CD45 + CD11b + F4/80+ macrophages have been observed in the bone microenvironment between IL-1β$^{-/-}$ and IL-1β$^{fl/fl}$ mice following intra-cardiac injection of E0771 cells (Ref. 13). It, therefore, appears that IL-1β may exert different effects on anti-tumour immunity in soft tissues compared with bone.

Myeloid-derived suppressor cells

MDSCs (Gr + CD11b+) are a heterogeneous population of cells of myeloid origin composed of immature macrophages, immature neutrophils and DCs. Therefore, the recruitment and mobilisation methods and functions of MDSC are similar to immunosuppressive neutrophils and macrophages (Ref. 66). MDSCs can induce apoptosis of cytotoxic T lymphocytes and natural killer cells to participate in the formation of an immune suppressed, pre-metastatic niche and subsequent development, progression and metastasis of breast cancer (Ref. 66). Tumour cells induce accumulation of MDSCs and tumour-derived IL-1β has been shown to facilitate an earlier and faster accumulation of MDSCs, in vivo (Ref. 67). IL-1β also stimulates MDSC-induced suppression of both CD4+ and CD8+ T cells via an arginase-dependent mechanism (Ref. 67). Moreover, pharmacological inhibition of IL-1R can reduce MDSC accumulation and inhibit tumour growth and metastasis by reducing the expression of G-CSF in mouse breast cancer models (Ref. 61).

T lymphocytes

T lymphocytes (CD4+ and CD8+) are an essential part of the immune system that regulate the adaptive immune response to cancer. CD8+ T cells kill tumour cells whereas CD4+ T cells assist B cells in regulating the immune response to a particular antigen. IL-1β has well-defined roles in facilitating adaptive T cell-mediated immunity and supporting expansion and maturation of CD4+ and CD8+ T cells in early tumour development (Ref. 22). Primary tumours isolated from IL-1β-deficient mice have increased CD8+ cytotoxic T cells and secrete high-concentrations of IFN-γ, TNF-α, granzyme B and IL-12 but have low levels of IL-10, which co-reduce immunosuppression (Ref. 53). However, as described, IL-1β can also mediate the recruitment and mobilisation of MDSCs to suppress T cell-mediated immunity (Ref. 11). In addition, it has been found that IL-1β can activate γδT cells to express IL-17, which in turn polarises and expands granulocyte colony stimulating factor-dependent neutrophils, thereby suppressing the production of CD8+ T cells and promoting breast cancer metastasis (Ref. 68). There is currently no evidence to show whether the level of T cell immunity stimulated by IL-1β is different between primary tumours and the bone metastatic niche, and further studies are required to understand the role of IL-1β in immune cell regulation of bone metastasis.

Discussion and concluding remarks

Inhibiting IL-1R1 activation (with the anti-IL-1β antibody, canakinumab or the IL-1R antagonist, anakinra) has shown significant and beneficial effects, almost eliminating bone metastasis in a number of pre-clinical models of breast cancer (Refs 5, 13, 18, 19). Similarly, canakinumab has been shown to have potent anti-cancer effects in the worldwide canakinumab Anti-inflammatory Thrombosis Outcomes Study (Ref. 69). However, it cannot be ignored that blocking IL-1R1 activity also increased the risk of primary tumour growth and outgrowth of disseminated mammary tumour cells in soft tissues in mice. Current data suggest that in the bone IL-1β stimulates tumour growth through expansion of the bone metastatic niche (Ref. 5) activation of previously dormant breast CSCs (Ref. 18) stimulation of the vicious cycle of bone metastasis (Ref. 5) and suppression of anti-cancer immune cells (Refs 13, 21, 53). In contrast, the role of IL-1β in the growth of primary tumours appears to be driven by immune cell regulation, but remains controversial. Therefore, in order to use anti-IL-1 therapies for the treatment of bone metastasis, it is likely that these would need to be combined with therapies that stimulate anti-tumour immunity (Fig. 3). Initial experiments combining anakinra with drugs that stimulate immunogenic tumour cell death (doxorubicin) or through stimulation of an anti-tumour T cell response (anti-PDL-1 antibodies) look extremely promising: combining anakinra with the standard of care for bone metastasis zoledronic acid and doxorubicin significantly reduced primary tumour growth and metastatic outgrowth in bone and soft tissues in 4T1 and E0771 mouse models (Ref. 13). Furthermore, treating IL-1β$^{-/-}$ mice with an anti-PD-1 antibody reversed IL-1β-induced 4T1 primary tumour growth and sequential combination with anti-IL-1 treatment followed by PDL-1 antibody completely abrogated tumour progression (Ref. 53). The positive outcomes of these preclinical studies provide strong rationale for the commencement of clinical trials combining IL-1-targeted treatments with anti-tumour immune stimulatory drugs for primary breast cancer and metastatic disease.

References

1. **Sung H et al.** (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* **71**, 209–249.
2. **Yang M et al.** (2019) Skeletal-related adverse events during bone metastasis of breast cancer: current status. *Discovery Medicine* **27**, 211–220.
3. **Coleman R et al.** (2012) Effects of bone-targeted agents on cancer progression and mortality. *Journal of the National Cancer Institute* **104**, 1059–1067.
4. **Pérez-Ramírez C et al.** (2017) Interleukins as new prognostic genetic biomarkers in non-small cell lung cancer. *Surgical Oncology* **26**, 278–285.
5. **Tulotta C et al.** (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. *Clinical Cancer Research* **25**, 2769–2782.
6. **Zabaleta J et al.** (2009) Cytokine genetic polymorphisms and prostate cancer aggressiveness. *Carcinogenesis* **30**, 1358–1362.
7. **Tengesdal IW et al.** (2021) Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. *Proceedings of the National Academy of Sciences* **118**, e2000915118.
8. **Gelfo V et al.** (2020) Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies. *International Journal of Molecular Sciences* **21**, 6009.
9. **Di Paolo NC and Shayakhmetov DM** (2016) Interleukin 1α and the inflammatory process. *Nature Immunology* **17**, 906–913.
10. **Rébé C and Ghiringhelli F** (2020) Interleukin-1β and cancer. *Cancers* **12**, 1791.
11. **Kiss M et al.** (2021) Inflammasome- and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity. *Cancer Immunology Research* **9**, 309–323.
12. **Wu T-C et al.** (2018) IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer. *Cancer Research* **78**, 5243–5258.
13. **Tulotta C et al.** (2021) IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. *NPJ Breast Cancer* **7**, 1–15.
14. **Lappano R et al.** (2020) The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). *Journal of Experimental & Clinical Cancer Research* **39**, 1–22.

15. **Nutter F *et al.*** (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. *Endocrine-Related Cancer* **21**, 327–341.

16. **Vilsmaier T *et al.*** (2016) Influence of circulating tumour cells on production of IL-1α, IL-1β and IL-12 in sera of patients with primary diagnosis of breast cancer before treatment. *Anticancer Research* **36**, 5227–5236.

17. **Lefley D *et al.*** (2019) Development of clinically relevant *in vivo* metastasis models using human bone discs and breast cancer patient-derived xenografts. *Breast Cancer Research* **21**, 1–21.

18. **Eyre R *et al.*** (2019) Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. *Nature Communications* **10**, 1–15.

19. **Holen I *et al.*** (2016) IL-1 drives breast cancer growth and bone metastasis *in vivo*. *Oncotarget* **7**, 75571.

20. **Voloshin T *et al.*** Blocking IL1b Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis.

21. **Guo B *et al.*** (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. *Scientific Reports* **6**, 1–12.

22. **Van Den Eeckhout B *et al.*** (2020) Interleukin-1 as innate mediator of T cell immunity. *Frontiers in Immunology* **11**, 621921.

23. **Li Y *et al.*** (2012) IL-1β promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. *Molecular Cancer* **11**, 1–13.

24. **Castaño Z *et al.*** (2018) IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. *Nature Cell Biology* **20**, 1084–1097.

25. **Riggio AI *et al.*** (2021) The lingering mysteries of metastatic recurrence in breast cancer. *British Journal of Cancer* **124**, 13–26.

26. **Hüsemann Y *et al.*** (2008) Systemic spread is an early step in breast cancer. *Cancer Cell* **13**, 58–68.

27. **Sosa MS *et al.*** (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. *Nature Reviews Cancer* **14**, 611–622.

28. **Lamouille S *et al.*** (2014) Molecular mechanisms of epithelial–mesenchymal transition. *Nature Reviews Molecular Cell Biology* **15**, 178–196.

29. **Najafi M *et al.*** (2019) Extracellular matrix (ECM) stiffness and degradation as cancer drivers. *Journal of Cellular Biochemistry* **120**, 2782–2790.

30. **Oh K *et al.*** (2016) IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. *BMC Cancer* **16**, 1–11.

31. **Mon NN *et al.*** (2017) Interleukin-1β activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells. *Oncology Letters* **13**, 955–960.

32. **Perez-Yepez EA *et al.*** (2014) A novel β-catenin signaling pathway activated by IL-1β leads to the onset of epithelial–mesenchymal transition in breast cancer cells. *Cancer Letters* **354**, 164–171.

33. **Fahey E and Doyle SL** (2019) IL-1 family cytokine regulation of vascular permeability and angiogenesis. *Frontiers in Immunology* **10**, 1426.

34. **Voronov E *et al.*** (2014) The role IL-1 in tumor-mediated angiogenesis. *Frontiers in Physiology* **5**, 114.

35. **Brown H *et al.*** (2012) Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo. *Clinical & Experimental Metastasis* **29**, 927–938.

36. **Ottewell PD** (2016) The role of osteoblasts in bone metastasis. *Journal of Bone Oncology* **5**, 124–127.

37. **Allocca G *et al.*** (2019) The bone metastasis niche in breast cancer: potential overlap with the haematopoietic stem cell niche in vivo. *Journal of Bone Oncology* **17**, 100244.

38. **Wang J *et al.*** (2006) The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. *Cancer and Metastasis Reviews* **25**, 573–587.

39. **Valdivia-Silva JE *et al.*** (2009) Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. *Cancer Letters* **283**, 176–185.

40. **Escobar P *et al.*** (2015) IL-1β produced by aggressive breast cancer cells is one of the factors that dictate their interactions with mesenchymal stem cells through chemokine production. *Oncotarget* **6**, 29034.

41. **Klein CA** (2009) Parallel progression of primary tumours and metastases. *Nature Reviews Cancer* **9**, 302–312.

42. **George CN *et al.*** (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre-and post-menopausal conditions. *Journal of Bone Oncology* **25**, 100317.

43. **Braun S *et al.*** (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. *New England Journal of Medicine* **353**, 793–802.

44. **Tjensvoll K *et al.*** (2019) Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. *BMC Cancer* **19**, 1–11.

45. **Jahanban-Esfahlan R *et al.*** (2019) Tumor cell dormancy: threat or opportunity in the fight against cancer. *Cancers* **11**, 1207.

46. **Tulotta C and Ottewell P** (2018) The role of IL-1B in breast cancer bone metastasis. *Endocrine-Related Cancer* **25**, R421–R434.

47. **Lawson DA *et al.*** (2015) Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. *Nature* **526**, 131–135.

48. **Balic M *et al.*** (2006) Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. *Clinical Cancer Research* **12**, 5615–5621.

49. **Sarmiento-Castro A *et al.*** (2020) Increased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH+ breast cancer stem cells. *Stem Cell Reports* **15**, 307–316.

50. **Rao S *et al.*** (2018) RANKL and RANK: from mammalian physiology to cancer treatment. *Trends in Cell Biology* **28**, 213–223.

51. **He Z *et al.*** (2020) Evaluation of genetic variants in IL-1B and its interaction with the predisposition of osteoporosis in the northwestern Chinese Han population. *The Journal of Gene Medicine* **22**, e3214.

52. **Voigt C *et al.*** (2017) Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. *Proceedings of the National Academy of Sciences* **114**, 12994–12999.

53. **Kaplanov I *et al.*** (2019) Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti–PD-1 for tumor abrogation. *Proceedings of the National Academy of Sciences* **116**, 1361–1369.

54. **Silvestre-Roig C *et al.*** (2016) Neutrophil heterogeneity: implications for homeostasis and pathogenesis. *Blood. The Journal of the American Society of Hematology* **127**, 2173–2181.

55. **Ohms M *et al.*** (2020) An attempt to polarize human neutrophils toward N1 and N2 phenotypes in vitro. *Frontiers in Immunology* **11**, 532.

56. **Chen LC *et al.*** (2012) Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. *EMBO Molecular Medicine* **4**, 1276–1293.

57. **Szczerba BM *et al.*** (2019) Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature* **566**, 553–557.

58. **Zeindler J *et al.*** (2019) Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer. *Breast Cancer Research and Treatment* **177**, 581–589.

59. **Xiao Y *et al.*** (2021) Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formation. *Cancer Cell* **39**, 423–437. e427.

60. **Zhao L *et al.*** (2018) Pharmacological activation of estrogen receptor beta augments innate immunity to suppress cancer metastasis. *Proceedings of the National Academy of Sciences* **115**, E3673–E3681.

61. **Gomes T *et al.*** (2019) IL-1β blockade attenuates thrombosis in a neutrophil extracellular trap-dependent breast cancer model. *Frontiers in Immunology* **10**, 2088.

62. **Chen Y *et al.*** (2019) Tumor-associated macrophages: an accomplice in solid tumor progression. *Journal of Biomedical Science* **26**, 1–13.

63. **Hou Z *et al.*** (2011) Macrophages induce COX-2 expression in breast cancer cells: role of IL-1β autoamplification. *Carcinogenesis* **32**, 695–702.

64. **Jang J-H *et al.*** (2020) Breast cancer cell–derived soluble CD44 promotes tumor progression by triggering macrophage IL1β production. *Cancer Research* **80**, 1342–1356.

65. **Hao N-B *et al.*** (2012) Macrophages in tumor microenvironments and the progression of tumors. *Clinical and Developmental Immunology* **2012**, 948098.

66. **Welte T *et al.*** (2016) Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. *Nature Cell Biology* **18**, 632–644.

67. **Bunt SK *et al.*** (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. *The Journal of Immunology* **176**, 284–290.

68. **Coffelt SB *et al.*** (2015) IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. *Nature* **522**, 345–348.

69. **Ridker PM *et al.*** (2017) Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *The Lancet* **390**, 1833–1842.